Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase2, Multi-Center, Multi-national, Randomized, Double-blind, Placebo-controlled Parallel-group Clinical Trial to Evaluate the Efficacy and Safety of RPC4046 in Adult Subjects With Eosinophilic Esophagitis

Next Previous
Trial Profile

A Phase2, Multi-Center, Multi-national, Randomized, Double-blind, Placebo-controlled Parallel-group Clinical Trial to Evaluate the Efficacy and Safety of RPC4046 in Adult Subjects With Eosinophilic Esophagitis

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 29 Nov 2023

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Cendakimab (Primary) ; Cendakimab (Primary)
  • Indications Eosinophilic oesophagitis
  • Focus Proof of concept; Therapeutic Use
  • Acronyms HEROES
  • Sponsors Celgene Corporation; Receptos

    • Most Recent Events

    • 17 Oct 2023 Results presented at the 31st United European Gastroenterology Week
    • 01 Apr 2023 Results of post hoc analysis assessing the dysphagia days as a measure of symptom improvement in patients with eosinophilic esophagitis from the HEROES study, published in the American Journal of Gastroenterology.
    • 27 Feb 2023 Results assessing systemic cendakimab administration impact on local esophageal gene expression in a substudy from this trial presented at the 2023 Annual Meeting of the American Academy of Allergy, Asthma and Immunology
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top